Skip to main content
ABL Bio Inc. logo

ABL Bio Inc. — Investor Relations & Filings

Ticker · 298380 ISIN · KR7298380007 LEI · 9884007BRC71Y64NK235 KO Professional, scientific and technical activities
Open in API
Filings indexed 368 across all filing types
Latest filing 2023-01-11 Legal Proceedings Report
Country KR South Korea
Listing KO 298380

About ABL Bio Inc.

https://www.ablbio.com

ABL Bio Inc. is a clinical-stage biotechnology company specializing in the development of bispecific antibody therapeutics for immuno-oncology and neurodegenerative diseases. The company leverages several proprietary platforms. For central nervous system disorders, its 'Grabody-B' technology is a blood-brain barrier (BBB) penetrating shuttle designed to enhance drug delivery to the brain. In immuno-oncology, ABL Bio develops 4-1BB based bispecific antibodies aimed at minimizing toxicity and overcoming resistance to existing immunotherapies. The company is also advancing a pipeline of antibody-drug conjugates (ADCs) with an improved therapeutic index for conditions such as rare blood cancers. ABL Bio actively progresses its therapeutic candidates through clinical development.

Recent filings

Filing Released Lang Actions
불성실공시법인지정예고(공시불이행)
Legal Proceedings Report Classification · 100% confidence The document is a formal notice from the Korea Exchange regarding the 'designation of an unfaithful disclosure corporation' (불성실공시법인지정예고) due to a delay in disclosure. This is a regulatory announcement concerning compliance and potential penalties, which falls under the category of general regulatory filings.
2023-01-11 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report on the Status of Large-Scale Shareholdings' (주식등의 대량보유상황보고서), which is a standard regulatory filing in South Korea (often referred to as a 5% report). It details changes in share ownership by major shareholders and special related parties, including reasons such as gifts (donations) and collateral loan agreements. This falls under the category of Major Shareholding Notification.
2023-01-06 Korean
투자판단관련주요경영사항(ABL301 관련 마일스톤 기술료 수령)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system regarding a 'Major Management Matter' (투자판단 관련 주요경영사항). It details the receipt of a milestone payment from a licensing agreement (ABL301 with Sanofi). Since this is a specific regulatory disclosure of a material event that does not fit into categories like M&A, dividends, or share issues, it falls under the general regulatory filing category.
2023-01-02 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by major shareholders and their special related parties, including specific transaction dates, methods (e.g., open market sales), and collateral agreements. This falls under the 'Major Shareholding Notification' category.
2022-12-27 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and specifically marked as a '정정신고' (Correction Report). It details changes to previously reported stock option grants, including adjustments to the number of recipients and the total number of shares granted due to employee departures. This falls under the category of capital structure and share-related changes, which is best classified as a share issue/capital change announcement.
2022-12-20 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement regarding the setting of a record date for the purpose of holding an Annual General Meeting (AGM). It does not contain the full proxy materials or the meeting presentation itself, but rather serves as a formal notice of the record date for shareholder rights. Given the nature of the announcement as a regulatory filing regarding meeting preparation, it fits best under the RNS category as a general regulatory announcement.
2022-12-15 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.